These findings not only highlight the efficacy and multifunctionality of TPL as a potential anti-liver cancer drug but also elucidate its mechanisms involving the inhibition of the JAK1/STAT3 signaling pathway and the activation of apoptosis-related pathways. The gene discussed is JAK1; the disease is liver cancer.